Vodobatinib in Patients With Dementia With Lewy Bodies
A phase 2a trial evaluated vodobatinib, an oral Abl tyrosine kinase inhibitor, for safety, tolerability, and biomarker effects in patients with...
We've collected the latest key neuroscience data releases, FDA announcements, and market activity for you.
Giving neuroscience decision-makers a front-row seat to real-time, unbiased opinions and insights from an international panel of expert Thought Leaders.
With thousands of updates occurring every year, Neuroscience ACCUMIN provides clear, timely, expert-driven guidance on what is impactful to inform strategic decision-making.
3,000+ currently investing in CNS product development
6,700 products with 1,350 unique mechanisms of action for CNS indications
15,000+ ongoing clinical trials involving CNS indications
See more Impact Score ratings and reactions with our Impact Archive
A curated collection of concise summaries and contextual backgrounds for significant neuroscience research.
A phase 2a trial evaluated vodobatinib, an oral Abl tyrosine kinase inhibitor, for safety, tolerability, and biomarker effects in patients with...
Two phase 3 trials and an open-label extension supported FDA approval of CAPLYTA (lumateperone) as adjunctive therapy for major depressive disorder,...
A consensus statement from the US National Network of Depression Centers outlined research priorities and ethical recommendations for the responsible...
See more Impact Score ratings and reactions with our Impact Archive
Enduring archive of discussion summaries and output from previous Congress Highlights sessions.
.webp?width=600&height=600&name=home_hero_image%20(77).webp)
Curious about joining us in person? You can find all of our planned, in-person neuroactivities from your member portal.
Dates and times for upcoming sessions
Locations and directions
Descriptions of each activity and what to expect
Any registration or RSVP details you’ll need
Whether you’re new to AccuminDesk or a returning participant, this is the best place to stay up to date on everything happening face-to-face.